Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements

With Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million will cross a couple of legal problems off its list.